^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CEACAM5-targeted antibody-drug conjugate

    Related drugs:
    6d
    CARMEN-LC06: Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (clinicaltrials.gov)
    P2, N=22, Terminated, Sanofi | Active, not recruiting --> Terminated; Sponsor decision, the decision is not related to any safety concern.
    Trial termination
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)
    14d
    CARMEN-GC01: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, Sanofi | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date • Combination therapy • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)
    20d
    The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat? (PubMed, Cancer Res Treat)
    Antibody Drug Conjugates (ADCs) are a novel class of therapeutics that structurally are composed by an antibody directed to a tumour epitope connected via a linker to a cytotoxic payload, and that have shown significant antitumor activity across a range of malignancies including lung cancer. In this article we review the pharmacology and design of ADCs, as well as we describe the results of different studies evaluating ADCs in lung cancer directed to several targets including HER2, HER3, TROP2, MET, CEACAM5 and DLL3, among others.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CEACAM5 (CEA Cell Adhesion Molecule 5) • DLL3 (Delta Like Canonical Notch Ligand 3)
    20d
    Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) (clinicaltrials.gov)
    P1/2, N=250, Not yet recruiting, EMD Serono Research & Development Institute, Inc.
    New P1/2 trial • Pan tumor • Metastases
    |
    precemtabart tocentecan (M9140)
    23d
    CEACAM5: Evaluation of SAR408701 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=254, Terminated, Sanofi | Active, not recruiting --> Terminated; Sponsor decision, The decision is not related to any safety concern.
    Trial termination • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression • CEACAM5 positive
    |
    tusamitamab ravtansine (SAR408701)
    29d
    Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (clinicaltrials.gov)
    P2, N=31, Terminated, Sanofi | Active, not recruiting --> Terminated; Sponsor decision, the decision is not related to any safety concern.
    Trial termination • Combination therapy • Checkpoint inhibition • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)
    2ms
    CARMEN-LC03: SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (clinicaltrials.gov)
    P3, N=389, Active, not recruiting, Sanofi | Trial completion date: Aug 2026 --> Jun 2025
    Trial completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    docetaxel • tusamitamab ravtansine (SAR408701)
    2ms
    Structural insights into epitope-paratope interactions of a monoclonal antibody targeting CEACAM5-expressing tumors. (PubMed, Nat Commun)
    The antibody-drug conjugate tusamitamab ravtansine specifically recognizes the A3-B3 domains of human CEACAM5 (hCEACAM5)...The cryogenic electron microscopy structure of the hCEACAM5A3-B3- tusa Fab complex (3.11 Å overall resolution) reveals a discontinuous epitope involving residues in the A3-B3 domains and an N-linked mannose at residue Asn612. Conformational constraints on the epitope-paratope interface enable tusamitamab to target hCEACAM5A3-B3 and distinguish CEACAM5 from other CEACAMs.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)
    2ms
    CARMEN-LC06: Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, Sanofi | Trial completion date: Sep 2024 --> Dec 2024
    Trial completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)
    2ms
    A Study of BG-C477 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=21, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    3ms
    A Study of BG-C477 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, BeiGene
    New P1 trial • Metastases
    4ms
    The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) (clinicaltrials.gov)
    P2, N=4, Terminated, Innovent Biologics (Suzhou) Co. Ltd. | N=130 --> 4 | Trial completion date: Dec 2025 --> Dec 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Nov 2023; strategy terminates development, the decision is not due to any safety-related issues
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    cisplatin • carboplatin • Tyvyt (sintilimab) • pemetrexed • tusamitamab ravtansine (SAR408701)
    4ms
    CARMEN-BT01: Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Sanofi | Trial primary completion date: Aug 2024 --> Feb 2024
    Trial primary completion date • Metastases
    |
    gemcitabine • tusamitamab ravtansine (SAR408701)
    7ms
    CARMEN-LC06: Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, Sanofi | Trial completion date: May 2024 --> Sep 2024
    Trial completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    tusamitamab ravtansine (SAR408701)
    7ms
    CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer. (PubMed, J Nucl Med)
    [89Zr]Zr-DFO-labetuzumab imaging was able to clearly delineate both neuroendocrine H660 xenografts and AR- DU145 in vivo but could not detect the AR-positive xenograft LNCaP. Immuno-PET imaging with [89Zr]Zr-DFO-labetuzumab is a promising diagnostic tool for AR- prostate cancer.
    Journal
    |
    AR (Androgen receptor) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    labetuzumab govitecan (IMMU-130)
    7ms
    Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic Drivers. (PubMed, BioDrugs)
    Several ADCs have already been approved for other cancers, such as breast cancer and urothelial carcinoma. This review summarizes the knowledge about the efficacy and tolerance profiles of ADCs targeting TROP2, HER2, HER3, CEACAM5 and c-MET in metastatic NSCLC with and without alterations in oncogenic drivers.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • PD-1 (Programmed cell death 1) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    EGFR mutation • ALK rearrangement
    7ms
    Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer. (PubMed, Cancers (Basel))
    Overall, 73.1% (49/67) of cervical cancer samples are CD138-positive with 38.8% (26/67) of cervical cancer samples showing at least moderate or high expression. (4) TROP2, CEACAM5 or CD138 do seem suitable for further clinical research and the data presented here might be used to guide further clinical trials with ADCs in advanced and recurrent cervical cancer patients.
    Journal
    |
    FOLR1 ( Folate receptor alpha ) • MSLN (Mesothelin) • CEACAM5 (CEA Cell Adhesion Molecule 5) • DLL3 (Delta Like Canonical Notch Ligand 3) • CD70 (CD70 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • GPNMB (Glycoprotein Nmb) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    TROP2 expression • CD70 expression • SDC1 positive
    7ms
    CARMEN-BT01: Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Sanofi | Trial primary completion date: Apr 2024 --> Aug 2024
    Trial primary completion date • Metastases
    |
    gemcitabine • tusamitamab ravtansine (SAR408701)
    8ms
    Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Sanofi | Trial completion date: Mar 2024 --> Sep 2024
    Trial completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)
    8ms
    Assessment of carcinoembryonic antigen-related cell adhesion molecule 5 expression by immunohistochemistry in real-world clinical samples of non-small cell lung cancer. (ASCO 2024)
    We assessed the expression of CEACAM5 by IHC on clinical biopsy/resection samples of consecutively diagnosed NSCLC from September 2022 to June 2023 at our institution, using the anti-CEACAM5 clone 769 antibody assay protocol developed for tusamitamab ravtansine clinical trials... Our data showed that approximately 20% of routinely diagnosed clinical NSCLC samples had high CEACAM5 expression by IHC. The interrater reliability on the determination of high CEACAM5 expression was moderate among the three pathologists. We highlighted the challenging aspects in the evaluation of this biomarker.
    Real-world evidence • Clinical • PD(L)-1 Biomarker • IO biomarker • Real-world
    |
    EGFR (Epidermal growth factor receptor) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    PD-L1 IHC 22C3 pharmDx • Oncomine™ Comprehensive Assay v3M
    |
    tusamitamab ravtansine (SAR408701)
    8ms
    TusaRav-QT: Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=56, Terminated, Sanofi | Trial completion date: Aug 2024 --> Mar 2024 | Active, not recruiting --> Terminated; Tusamitamab ravtansine clinical development program is discontinued as CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival. The decision is not related to any safety concern.
    Trial completion date • Trial termination • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)
    9ms
    Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: May 2025 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • capecitabine • precemtabart tocentecan (M9140)
    10ms
    Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, EMD Serono Research & Development Institute, Inc. | N=31 --> 180 | Trial completion date: Nov 2023 --> May 2025 | Trial primary completion date: Nov 2023 --> Apr 2024
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • capecitabine • precemtabart tocentecan (M9140)
    10ms
    INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (clinicaltrials.gov)
    P2, N=0, Withdrawn, Erasmus Medical Center | N=60 --> 0 | Trial completion date: May 2025 --> Feb 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2025 --> Feb 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    tusamitamab ravtansine (SAR408701)
    10ms
    CEACAM5: Evaluation of SAR408701 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=254, Active, not recruiting, Sanofi | Trial completion date: Feb 2024 --> Aug 2024
    Trial completion date • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression • CEACAM5 positive
    |
    tusamitamab ravtansine (SAR408701)
    10ms
    CARMEN-LC06: Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | N=38 --> 22 | Trial completion date: Dec 2024 --> May 2024 | Trial primary completion date: Dec 2024 --> Jan 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)
    10ms
    Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • tusamitamab ravtansine (SAR408701)
    10ms
    Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)
    10ms
    CARMEN-LC03: SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (clinicaltrials.gov)
    P3, N=411, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    docetaxel • tusamitamab ravtansine (SAR408701)
    10ms
    CARMEN-BT01: Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • tusamitamab ravtansine (SAR408701)
    11ms
    Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=92, Terminated, Gilead Sciences | Withdrawn --> Terminated
    Trial termination • Metastases
    |
    Trodelvy (sacituzumab govitecan-hziy) • labetuzumab govitecan (IMMU-130)
    12ms
    CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. (PubMed, Curr Cancer Drug Targets)
    These data suggest that further preclinical and clinical development of CT109-SN-38 is warranted.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CEACAM6 (CEA Cell Adhesion Molecule 6)
    1year
    CARMEN-GC01: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, Sanofi | Trial completion date: Oct 2023 --> Jun 2024
    Trial completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)
    1year
    CARMEN-BT01: Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=94, Recruiting, Sanofi | Trial completion date: Jan 2025 --> Aug 2025 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    gemcitabine • tusamitamab ravtansine (SAR408701)
    1year
    A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. (PubMed, Acta Pharmacol Sin)
    In BxPC-3 and MKN-45 xenograft mice, administration of UdADC B9-MMAE (5 mg/kg, i.v.) every 2 days for 4 times markedly inhibited the tumor growth without significant change in body weight. This study may have significant implications for the design of next-generation ADCs.
    Preclinical • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    1year
    SCS-03: How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities (IASLC-NACLC 2023)
    Promising initial evidence demonstrates the potential of targeting CEACAM5 to provide additional therapeutic options for patients with lung cancer, and several ongoing clinical trials are evaluating CEACAM5-targeting agents across different settings in NSCLC.In this live satellite symposium, renowned experts will discuss the clinical rationale for targeting CEACAM5, explore how strategies to test for CEACAM5 fit into larger testing paradigms in NSCLC, and review ongoing research efforts to develop antibody-drug conjugates—including novel CEACAM5-directed therapies—for the treatment of advanced NSCLC. These discussions will be supplemented by instructive animations that will help to explain these complicated concepts more simply.
    IO biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    1year
    SGNCEA5C-001: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=410, Recruiting, Seagen Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    1year
    CEACAM5: Evaluation of SAR408701 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=266, Active, not recruiting, Sanofi | Trial completion date: Aug 2023 --> Feb 2024
    Trial completion date • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression • CEACAM5 positive
    |
    tusamitamab ravtansine (SAR408701)
    1year
    Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody-Drug Conjugates. (PubMed, Cancers (Basel))
    Despite the negative results of rovalpituzumab tesirine (Rova-T), other ADCs targeting different antigens, such as B7-H3, seizure-related homolog 6 (SEZ6), and CEACAM5, have also been investigated in clinical trials, including for SCLC, and their results suggest preliminary activity, either alone or in combination with other therapies. More recently, sacituzumab govitecan, an anti-TROP2 ADC, demonstrated promising activity in lung cancer, including SCLC. Furthermore, an anti-B7-H3 (CD276), ifinatamab deruxtecan (DS7300A), showed a high response rate and durable responses in heavily pretreated SCLC...Further studies are needed to determine their efficacy and safety and the best location in the treatment algorithm for SCLC. In this review, we aim to collect and describe the results regarding the past, the present, and the future of ADCs in SCLC.
    Review • Journal
    |
    CD276 (CD276 Molecule) • CEACAM5 (CEA Cell Adhesion Molecule 5) • SEZ6 (Seizure Related 6 Homolog)
    |
    Trodelvy (sacituzumab govitecan-hziy) • Rova-T (rovalpituzumab tesirine) • ifinatamab deruxtecan (DS-7300)
    1year
    Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) (clinicaltrials.gov)
    P2, N=215, Recruiting, Sanofi | Trial primary completion date: May 2024 --> Sep 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • tusamitamab ravtansine (SAR408701)
    1year
    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=410, Not yet recruiting, Seagen Inc.
    New P1 trial • Metastases
    1year
    CARMEN-LC03: SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (clinicaltrials.gov)
    P3, N=450, Recruiting, Sanofi | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    docetaxel • tusamitamab ravtansine (SAR408701)